Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases

Patients with preexisting autoimmune disease (pAID) are generally excluded from clinical trials for immune checkpoint inhibitors (ICIs) for cancer due to concern of flaring pAID. In this multi-center, retrospective observational study, we compared safety of ICI combination (two ICI agents) versus mo...

Description complète

Détails bibliographiques

Auteurs principaux:	Pankti Reid, Sabina Sandigursky, Juhee Song, Maria A. Lopez-Olivo, Houssein Safa, Samuel Cytryn, Elizaveta Efuni, Maryam Buni, Anna Pavlick, Michelle Krogsgaard, Osama Abu-Shawer, Mehmet Altan, Jeffrey S. Weber, Osama E. Rahma, Maria E. Suarez-Almazor, Adi Diab, Noha Abdel-Wahab
Format:	Artigo
Langue:	Inglês
Publié:	Taylor & Francis Group 2023-12-01
Collection:	OncoImmunology
Sujets:	Preexisting autoimmune disease immune-related adverse events cancer immunotherapy toxicity autoimmune disease flare combination immune checkpoint inhibitor
Accès en ligne:	https://www.tandfonline.com/doi/10.1080/2162402X.2023.2261264
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!